98 related articles for article (PubMed ID: 28099366)
1. Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?
Haueis SA; Kränzlin P; Mangana J; Cheng PF; Urosevic-Maiwald M; Braun RP; Levesque MP; Dummer R; Goldinger SM
Melanoma Res; 2017 Jun; 27(3):231-237. PubMed ID: 28099366
[TBL] [Abstract][Full Text] [Related]
2. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
[TBL] [Abstract][Full Text] [Related]
3. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.
Chan MM; Haydu LE; Menzies AM; Azer MW; Klein O; Lyle M; Clements A; Guminski A; Kefford RF; Long GV
Cancer; 2014 Oct; 120(20):3142-53. PubMed ID: 24985732
[TBL] [Abstract][Full Text] [Related]
4. BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response.
Desvignes C; Abi Rached H; Templier C; Drumez E; Lepesant P; Desmedt E; Mortier L
Melanoma Res; 2017 Jun; 27(3):281-287. PubMed ID: 28240681
[TBL] [Abstract][Full Text] [Related]
5. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
Valpione S; Carlino MS; Mangana J; Mooradian MJ; McArthur G; Schadendorf D; Hauschild A; Menzies AM; Arance A; Ascierto PA; Di Giacomo A; de Rosa F; Larkin J; Park JJ; Goldinger SM; Sullivan RJ; Xu W; Livingstone E; Weichenthal M; Rai R; Gaba L; Long GV; Lorigan P
Eur J Cancer; 2018 Mar; 91():116-124. PubMed ID: 29360604
[TBL] [Abstract][Full Text] [Related]
6. Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma.
Aya F; Fernandez-Martinez A; Gaba L; Victoria I; Tosca M; Pineda E; Gascon P; Prat A; Arance A
Clin Transl Oncol; 2017 Jan; 19(1):119-124. PubMed ID: 27147251
[TBL] [Abstract][Full Text] [Related]
7. BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis.
Maxwell R; Garzon-Muvdi T; Lipson EJ; Sharfman WH; Bettegowda C; Redmond KJ; Kleinberg LR; Ye X; Lim M
Int J Cancer; 2017 Jun; 140(12):2716-2727. PubMed ID: 27342756
[TBL] [Abstract][Full Text] [Related]
8. BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study.
Mastorakos P; Xu Z; Yu J; Hess J; Qian J; Chatrath A; Taylor DG; Kondziolka D; Warnick R; Chiang V; Sheehan J
Neurosurgery; 2019 Apr; 84(4):868-880. PubMed ID: 29846702
[TBL] [Abstract][Full Text] [Related]
9. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
10. Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.
Amaravadi RK; Hamilton KE; Ma X; Piao S; Portillo AD; Nathanson KL; Carlino MS; Long GV; Puzanov I; Xu X; Morrissette JJ; Tsai KY; Flaherty KT; Sosman JA; Goodman GR; McArthur GA; Rustgi AK; Metz DC; Schuchter LM; Chapman PB; Sepulveda AR
Clin Cancer Res; 2015 Dec; 21(23):5215-21. PubMed ID: 26202952
[TBL] [Abstract][Full Text] [Related]
11. Study of metastatic kinetics in metastatic melanoma treated with B-RAF inhibitors: Introducing mathematical modelling of kinetics into the therapeutic decision.
Hartung N; Huynh CT; Gaudy-Marqueste C; Flavian A; Malissen N; Richard-Lallemand MA; Hubert F; Grob JJ
PLoS One; 2017; 12(5):e0176080. PubMed ID: 28472075
[TBL] [Abstract][Full Text] [Related]
12. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis.
Patel KR; Chowdhary M; Switchenko JM; Kudchadkar R; Lawson DH; Cassidy RJ; Prabhu RS; Khan MK
Melanoma Res; 2016 Aug; 26(4):387-94. PubMed ID: 27223498
[TBL] [Abstract][Full Text] [Related]
13. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
14. Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?
Tolk H; Satzger I; Mohr P; Zimmer L; Weide B; Schäd S; Gutzmer R
Melanoma Res; 2015 Aug; 25(4):362-6. PubMed ID: 26061438
[TBL] [Abstract][Full Text] [Related]
15. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
16. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
17. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment.
Ly D; Bagshaw HP; Anker CJ; Tward JD; Grossmann KF; Jensen RL; Shrieve DC
J Neurosurg; 2015 Aug; 123(2):395-401. PubMed ID: 25768829
[TBL] [Abstract][Full Text] [Related]
18. Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases.
Patel BG; Ahmed KA; Johnstone PA; Yu HH; Etame AB
Melanoma Res; 2016 Aug; 26(4):382-6. PubMed ID: 26926151
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
Scholtens A; Geukes Foppen MH; Blank CU; van Thienen JV; van Tinteren H; Haanen JB
Eur J Cancer; 2015 Mar; 51(5):642-52. PubMed ID: 25690538
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
Ackerman A; Klein O; McDermott DF; Wang W; Ibrahim N; Lawrence DP; Gunturi A; Flaherty KT; Hodi FS; Kefford R; Menzies AM; Atkins MB; Long GV; Sullivan RJ
Cancer; 2014 Jun; 120(11):1695-701. PubMed ID: 24577748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]